Multivalent Human Papillomavirus L1 DNA Vaccination Utilizing Electroporation

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kwak, Kihyuck ^a   Jiang, Rosie ^a   Jagu, Subhashini ^a   Wang, Joshua W ^a   Wang, Chenguang ^b   Christensen, Neil D ^c   Roden, Richard B S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN L2; DNA VACCINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DNA IMMUNIZATION; DOSE RESPONSE; DRUG DOSE COMPARISON; ELECTROPORATION; EXPRESSION VECTOR; FEMALE; GENE GUN IMMUNIZATION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TREATMENT DURATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CAPSID PROTEINS; CELL LINE; ELECTROPORATION; HUMANS; MICE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; VACCINES, DNA;

HUMAN PAPILLOMAVIRUS; MUS;

EID: 84875414266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060507     Document Type: Article

References (81)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of pathology 189: 12-19.
2. Moscicki AB, (2010) Human papillomavirus disease and vaccines in adolescents. Adolescent medicine: state of the art reviews 21: 347-363, x-xi.
3. Parkin DM, Bray F, (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24Suppl 3: S3/11-25.
4. Kreimer AR, Clifford GM, Boyle P, Franceschi S, (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14: 467-475.
5. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT, (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences of the United States of America 89: 12180-12184.
6. Rose RC, Bonnez W, Reichman RC, Garcea RL, (1993) Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. Journal of virology 67: 1936-1944.
7. Nardelli-Haefliger D, Roden R, Balmelli C, Potts A, Schiller J, et al. (1999) Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. Journal of virology 73: 9609-9613.
8. Rose RC, Bonnez W, Da Rin C, McCance DJ, Reichman RC, (1994) Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. The Journal of general virology 75 (Pt 9): 2445-2449.
9. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS, (1996) Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224: 477-486.
10. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, et al. (1996) Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. Journal of virology 70: 3298-3301.
11. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, et al. (1996) In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. Journal of virology 70: 5875-5883.
12. Burd EM, (2003) Human papillomavirus and cervical cancer. Clinical microbiology reviews 16: 1-17.
13. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International journal of cancer Journal international du cancer 111: 278-285.
14. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. The Journal of infectious diseases 199: 926-935.
15. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, et al. (2007) Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Human vaccines 3: 109-115.
16. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D, (2011) A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. Journal of virology 85: 13253-13259.
17. Schiller JT, Lowy DR, (2009) Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. The Journal of infectious diseases 200: 166-171.
18. Campo MS, O'Neil BW, Grindlay GJ, Curtis F, Knowles G, et al. (1997) A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 234: 261-266.
19. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, (1999) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. Journal of virology 73: 6188-6190.
20. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
21. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. Journal of virology 81: 13927-13931.
22. Roden RB, Weissinger EM, Henderson DW, Booy F, Kirnbauer R, et al. (1994) Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. Journal of virology 68: 7570-7574.
23. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. Journal of the National Cancer Institute 101: 782-792.
24. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, et al. (2012) Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PloS one 7: e39741.
25. Tumban E, Peabody J, Peabody DS, Chackerian B, (2011) A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS ONE 6: e23310.
26. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Journal of virology 83: 10085-10095.
27. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. International journal of cancer Journal international du cancer 118: 3030-3044.
28. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, et al. (1997) Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. Journal of virology 71: 2988-2995.
29. Chen XS, Casini G, Harrison SC, Garcea RL, (2001) Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. Journal of molecular biology 307: 173-182.
30. Schadlich L, Senger T, Kirschning CJ, Muller M, Gissmann L, (2009) Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine 27: 1511-1522.
31. Abdulhaqq SA, Weiner DB, (2008) DNA vaccines: developing new strategies to enhance immune responses. Immunologic research 42: 219-232.
32. Schadlich L, Senger T, Gerlach B, Mucke N, Klein C, et al. (2009) Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. Journal of virology 83: 7690-7705.
33. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
34. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, et al. (2004) TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21: 107-119.
35. Krug A, Luker GD, Barchet W, Leib DA, Akira S, et al. (2004) Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103: 1433-1437.
36. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A, (2003) Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. The Journal of experimental medicine 198: 513-520.
37. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, et al. (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nature immunology 11: 395-402.
38. Ishikawa H, Barber GN, (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455: 674-678.
39. Peng B, Zhao Y, Lu H, Pang W, Xu Y, (2005) In vivo plasmid DNA electroporation resulted in transfection of satellite cells and lasting transgene expression in regenerated muscle fibers. Biochemical and biophysical research communications 338: 1490-1498.
40. Fuller DH, Loudon P, Schmaljohn C, (2006) Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40: 86-97.
41. Steele KE, Stabler K, VanderZanden L, (2001) Cutaneous DNA vaccination against Ebola virus by particle bombardment: histopathology and alteration of CD3-positive dendritic epidermal cells. Veterinary pathology 38: 203-215.
42. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, et al. (1999) High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proceedings of the National Academy of Sciences of the United States of America 96: 4262-4267.
43. Cukjati D, Batiuskaite D, Andre F, Miklavcic D, Mir LM, (2007) Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 70: 501-507.
44. Trollet C, Bloquel C, Scherman D, Bigey P, (2006) Electrotransfer into skeletal muscle for protein expression. Current gene therapy 6: 561-578.
45. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R, (2006) Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24: 4490-4493.
46. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, et al. (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22: 2489-2493.
47. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, et al. (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PloS one 6: e19252.
48. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, et al. (2012) Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses. Science translational medicine 4: 155ra138.
49. Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, et al. (2013) Optimization of Multimeric Human Papillomavirus L2 Vaccines. PLoS ONE 8: e55538.
50. Sundaram P, Tigelaar RE, Xiao W, Brandsma JL, (1998) Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine 16: 613-623.
51. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, et al. (1996) Protection against papillomavirus with a polynucleotide vaccine. The Journal of infectious diseases 173: 314-320.
52. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, et al. (2009) DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Human gene therapy 20: 1269-1278.
53. Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, et al. (2011) Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 29: 795-803.
54. Sardesai NY, Weiner DB, (2011) Electroporation delivery of DNA vaccines: prospects for success. Current opinion in immunology 23: 421-429.
55. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I, (1999) Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. Journal of virology 73: 4972-4982.
56. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, et al. (2001) Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20: 862-869.
57. Leder C, Kleinschmidt JA, Wiethe C, Muller M, (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. Journal of virology 75: 9201-9209.
58. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
59. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, et al. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. Journal of virology 67: 6929-6936.
60. Hitzeroth, II, Passmore JA, Shephard E, Stewart D, Muller M, et al. (2009) Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine 27: 6432-6434.
61. Kim D, Gambhira R, Karanam B, Monie A, Hung CF, et al. (2008) Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 26: 351-360.
62. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, et al. (2011) Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. The Journal of general virology 92: 128-140.
63. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, et al. (2011) DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. The Lancet infectious diseases 11: 916-924.
64. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
65. Geraets D, Alemany L, Guimera N, de Sanjose S, de Koning M, et al. (2012) Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. The Journal of pathology.
66. Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, et al. (2001) L1 interaction domains of papillomavirus L2 necessary for viral genome encapsidation. J Virol 75: 4332-4342.
67. Finnen RL, Erickson KD, Chen XS, Garcea RL, (2003) Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 77: 4818-4826.
68. Chen HS, Bromberg-White J, Conway MJ, Alam S, Meyers C, (2010) Study of infectious virus production from HPV18/16 capsid chimeras. Virology 405: 289-299.
69. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, et al. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67: 6929-6936.
70. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.
71. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of Human Papillomavirus L2. J Virol 81: 13927-13931.
72. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, et al. (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8: 260-270.
73. Buonamassa DT, Greer CE, Capo S, Yen TS, Galeotti CL, et al. (2002) Yeast coexpression of human papillomavirus types 6 and 16 capsid proteins. Virology 293: 335-344.
74. Gasparic M, Rubio I, Thones N, Gissmann L, Muller M, (2007) Prophylactic DNA immunization against multiple papillomavirus types. Vaccine 25: 4540-4553.
75. Senger T, Becker MR, Schadlich L, Waterboer T, Gissmann L, (2009) Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. Journal of virology 83: 12692-12701.
76. Fleury MJ, Touze A, Maurel MC, Moreau T, Coursaget P, (2009) Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein science: a publication of the Protein Society 18: 1425-1438.
77. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, et al. (2007) Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. The Journal of biological chemistry 282: 31803-31811.
78. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, et al. (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223: 174-184.
79. Hitzeroth II, Passmore JA, Shephard E, Stewart D, Muller M, et al. (2009) Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine 27: 6432-6434.
80. Bronnimann MP, Chapman JA, Park CK, Campos SK, (2013) A Transmembrane Domain and GxxxG Motifs within L2 Are Essential for Papillomavirus Infection. Journal of virology 87: 464-473.
81. Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, et al. (1999) Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18: 18-28.